Daclatasvir and Sofosbuvir 60mg/400mg Tablets are fixed-dose antiviral tablets containing Daclatasvir 60 mg and Sofosbuvir 400 mg. This combination has been used in the management of chronic Hepatitis C virus (HCV) infection. The World Health Organization (WHO) has listed a 60mg/400mg film-coated Daclatasvir/Sofosbuvir tablet as a prequalified finished pharmaceutical product for the Hepatitis B and C therapeutic area.
For UAE-based pharmaceutical distributors, medical suppliers, healthcare organizations, and authorized buyers looking to source this combination from India, working with an experienced Daclatasvir and Sofosbuvir 60mg/400mg Tablets exporter from India can help streamline international pharmaceutical procurement.
Daclatasvir and Sofosbuvir 60mg/400mg Tablets: Product Overview
Each tablet contains:
- Daclatasvir – 60 mg
- Sofosbuvir – 400 mg
- Film-coated tablet formulation
Daclatasvir and Sofosbuvir work against different viral targets involved in HCV replication. The combination is used as part of an HCV treatment regimen according to the patient's clinical condition, HCV genotype, previous treatment history, liver status, and applicable treatment guidelines.
The exact treatment regimen and duration should always be determined by a qualified healthcare professional.
Exporting Daclatasvir and Sofosbuvir from India to UAE
India has a significant pharmaceutical manufacturing and export sector, making Indian suppliers an important source for medicines and pharmaceutical products internationally. WHO records also show a prequalified Daclatasvir (dihydrochloride)/Sofosbuvir 60mg/400mg finished pharmaceutical product manufactured by an Indian pharmaceutical company.
For UAE buyers, pharmaceutical imports must meet applicable UAE regulatory and import requirements. The UAE Ministry of Health and Prevention (MOHAP) states that registration of a conventional pharmaceutical product is a prerequisite for the import service, and the registration process includes technical documentation and regulatory review.
What UAE Buyers Should Check Before Importing
When sourcing Daclatasvir and Sofosbuvir 60mg/400mg Tablets from India, buyers should verify:
- Product name and active ingredients
- Strength and dosage form
- Manufacturer details
- Batch number and expiry date
- Certificate of Analysis (CoA)
- Product registration or applicable regulatory status
- Packaging and labeling requirements
- Shipping and documentation requirements
- Import authorization through the appropriate UAE channel
MOHAP's medicine import service specifies that licensed local entities are involved in the import process and that an initial import permit may need to be obtained before shipment from the country of origin.
Why Source Daclatasvir and Sofosbuvir from an Indian Exporter?
An established Indian pharmaceutical exporter can support international buyers with product sourcing, commercial documentation, batch-related documents, packaging information, and export coordination.
For UAE distributors and pharmaceutical procurement companies, it is important to select a supplier that can provide transparent product information and documentation appropriate for the intended market.
Request a Quote for Daclatasvir and Sofosbuvir 60mg/400mg
If you are a UAE pharmaceutical distributor, wholesaler, healthcare procurement company, or authorized importer looking to source Daclatasvir and Sofosbuvir 60mg/400mg Tablets from India, you can contact an Indian pharmaceutical exporter to discuss product availability, packaging, quantities, documentation, and shipping requirements.
Note: Daclatasvir and Sofosbuvir are prescription medicines. Availability, registration, importation, and use are subject to applicable UAE regulations and medical supervision. This article is for general informational purposes and does not replace professional medical advice.